Dana E. Selley
About
Dana E. Selley is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology.
According to data from OpenAlex, Dana E. Selley has authored 142 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Cellular and Molecular Neuroscience, 83 papers in Molecular Biology and 55 papers in Pharmacology. Recurrent topics in Dana E. Selley's work include Receptor Mechanisms and Signaling (67 papers), Neuropeptides and Animal Physiology (62 papers) and Cannabis and Cannabinoid Research (53 papers). Dana E. Selley is often cited by papers focused on Receptor Mechanisms and Signaling (67 papers), Neuropeptides and Animal Physiology (62 papers) and Cannabis and Cannabinoid Research (53 papers). Dana E. Selley collaborates with scholars based in United States, United Kingdom and Greece. Dana E. Selley's co-authors include Steven R. Childers, Laura J. Sim‐Selley, Laura J. Sim, Aron H. Lichtman, Benjamin F. Cravatt, James J. Burston, Steven G. Kinsey, C. S. Breivogel, Joel E. Schlosburg and Michael P. Cassidy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Neuron.
In The Last Decade
Dana E. Selley
140 papers receiving 7.3k citations
Hit Papers
Peers
Dana E. Selley
Steven R. Childers United States
Alice C. Young United States
Mario van der Stelt Netherlands
Laura J. Sim‐Selley United States
Mary E. Abood United States
Michelle Glass New Zealand
Jacob Barg Israel
Zvi Vogel Israel
Eberhard Schlicker Germany
Maria Grazia Cascio Italy
Citations per year, relative to Dana E. Selley Dana E. Selley (= 1×)
peers
Steven R. Childers
Countries citing papers authored by Dana E. Selley
Since
Specialization
Citations
This map shows the geographic impact of Dana E. Selley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana E. Selley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana E. Selley more than expected).
Fields of papers citing papers by Dana E. Selley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dana E. Selley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana E. Selley. The network helps show where Dana E. Selley may publish in the future.
Co-authorship network of co-authors of Dana E. Selley
This figure shows the co-authorship network connecting the top 25 collaborators of Dana E. Selley. A scholar is included among the top collaborators of Dana E. Selley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana E. Selley. Dana E. Selley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gutman, Eugene S., Arthur E. Jacobson, Kenner C. Rice, et al.. (2023). Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor (MOR ) ligands in female and male mice. II . Effects of novel MOR ‐selective phenylmorphans with high‐to‐low MOR efficacy. Pharmacology Research & Perspectives. 11(4). e01111–e01111.
2.
Obeng, Samuel, Yunyun Yuan, Abdulmajeed M. Jali, Dana E. Selley, & Yan Zhang. (2018). In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator. European Journal of Pharmacology. 827. 32–40.
3.
Grim, Travis W., Bogna M. Ignatowska‐Jankowska, Tao Qing, et al.. (2016). Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. Journal of Basic and Clinical Physiology and Pharmacology. 27(3). 217–228.
4.
Arnatt, Christopher K., Yunyun Yuan, Ruturaj Masvekar, et al.. (2016). Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization. Bioorganic & Medicinal Chemistry. 24(22). 5969–5987.
5.
Viader, Andreu, Jacqueline L. Blankman, Peng Zhong, et al.. (2015). Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action. Cell Reports. 12(5). 798–808.
6.
Lazenka, Matthew F., et al.. (2014). Delta FosB and AP-1-mediated transcription modulate cannabinoid CB1 receptor signaling and desensitization in striatal and limbic brain regions. Biochemical Pharmacology. 91(3). 380–389.
7.
Ahmed, Mostafa H., Glen E. Kellogg, Dana E. Selley, Martin K. Safo, & Yan Zhang. (2014). Predicting the molecular interactions of CRIP1a–cannabinoid 1 receptor with integrated molecular modeling approaches. Bioorganic & Medicinal Chemistry Letters. 24(4). 1158–1165.
8.
Zaidi, Saheem A., Christopher K. Arnatt, Hengjun He, et al.. (2013). Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the ‘message–address’ concept in development of mu opioid receptor selective antagonists. Bioorganic & Medicinal Chemistry. 21(21). 6405–6413.
9.
Hoot, Michelle R., et al.. (2011). Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus. Brain Research. 1406. 1–7.
10.
Thorpe, Andrew, Joel E. Schlosburg, Benjamin F. Cravatt, et al.. (2010). FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration. Neuropsychopharmacology. 35(8). 1775–1787.
11.
Nguyen, Phong, Dana E. Selley, & Laura J. Sim‐Selley. (2010). Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain. NeuroImage. 52(4). 1243–1251.
12.
Kalvass, J. Cory, Emily R. Olson, Michael P. Cassidy, Dana E. Selley, & Gary M. Pollack. (2007). Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical Data. Journal of Pharmacology and Experimental Therapeutics. 323(1). 346–355.
13.
Cassidy, Michael P., Lauren Collier, Billy R. Martin, et al.. (2007). Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to Δ9-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. 324(2). 664–673.
14.
Paugh, Steven W., Michael P. Cassidy, Hengjun He, et al.. (2006). Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid Receptor. Molecular Pharmacology. 70(1). 41–50.
15.
Sim‐Selley, Laura J., et al.. (2006). Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration. Molecular Pharmacology. 70(3). 986–996.
16.
Huffman, John W., Dana E. Selley, Hengjun He, et al.. (2005). 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorganic & Medicinal Chemistry Letters. 15(18). 4110–4113.
17.
Cichewicz, Diana L., et al.. (2004). Mu and delta opioid-stimulated [35S]GTPγS binding in brain and spinal cord of polyarthritic rats. European Journal of Pharmacology. 504(1-2). 33–38.
18.
Thompson, Chad M., et al.. (2004). Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors. Journal of Pharmacology and Experimental Therapeutics. 308(2). 547–554.
19.
Sim, Laura J., Dana E. Selley, & Steven R. Childers. (2003). Autoradiographic Visualization in Brain of Receptor-G Protein Coupling Using [<sup>35</sup>S]GTPγS Binding. Humana Press eBooks. 83. 117–132.
20.
Selley, Dana E., C. S. Breivogel, Anne Zimmer, et al.. (2001). Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G‐protein activation. Journal of Neurochemistry. 77(4). 1048–1057.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Steven R. Childers Breakdown of academic impact, for papers by Alice C. Young Breakdown of academic impact, for papers by Mario van der Stelt Breakdown of academic impact, for papers by Laura J. Sim‐Selley Breakdown of academic impact, for papers by Mary E. Abood Breakdown of academic impact, for papers by Michelle Glass Breakdown of academic impact, for papers by Jacob Barg Breakdown of academic impact, for papers by Zvi Vogel Breakdown of academic impact, for papers by Eberhard Schlicker Breakdown of academic impact, for papers by Maria Grazia Cascio